{"id":"W2923666301","doi":"10.1038/s41408-019-0196-6","title":"Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study","year":2019,"lang":"en","type":"article","venue":"Blood Cancer Journal","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":213,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Kite Pharma; National Institute for Health and Care Research; National Institutes of Health; American Society of Hematology; Cancer Research UK; National Cancer Institute; University College London; Celgene; University College London Hospitals NHS Foundation Trust; Sanofi; GlaxoSmithKline; Amgen; Bristol-Myers Squibb","keywords":"Medicine; Tolerability; Internal medicine; Refractory (planetary science); Multiple myeloma; Interim analysis; Lenalidomide; Transplantation; Phases of clinical research; Clinical trial; Oncology; Gastroenterology; Surgery; Adverse effect; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005277405,0.0003380826,0.0006537765,0.0003128974,0.0002020097,0.00008865875,0.000174498,0.00009896996,0.0007309141],"category_scores_gemma":[0.0001162264,0.0002562445,0.00009609563,0.0002110087,0.00006195488,0.0002863882,0.00007439138,0.0009679032,0.00007181878],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001936236,"about_ca_system_score_gemma":0.000330829,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001238323,"about_ca_topic_score_gemma":0.0005033737,"domain_scores_codex":[0.9971724,0.0003538014,0.0005850344,0.000593145,0.000734115,0.0005614877],"domain_scores_gemma":[0.9982393,0.0002359313,0.0002137534,0.0004917064,0.0001303813,0.0006889121],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02168485,0.01526343,0.8520634,0.00003520083,0.0006778422,0.002892285,0.001797475,0.00008845536,0.03872325,0.000002273555,0.00008636704,0.06668517],"study_design_scores_gemma":[0.1447652,0.00506332,0.8435265,0.0005252701,0.0002396646,0.0001082062,0.0009312716,0.0008136119,0.002669542,0.00001334619,0.001062943,0.0002811598],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957554,0.001952897,0.000006100634,0.0002757844,0.000329024,0.00129659,0.0001503141,0.00003677527,0.0001971225],"genre_scores_gemma":[0.9968053,0.00195826,0.0002296502,0.0002150479,0.0003668877,0.00002278464,0.0001525152,0.0000544095,0.0001952176],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1230803,"threshold_uncertainty_score":0.999989,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02122107329605373,"score_gpt":0.3503603800385909,"score_spread":0.3291393067425372,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}